Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Frequently asked questions
What sector does Astellas Pharma Inc. (4503) operate in?
Astellas Pharma Inc. belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is Astellas Pharma Inc. (4503) current stock price?
As of the latest data, Astellas Pharma Inc. stock price is ¥2,348, with a previous close of ¥2,328. Astellas Pharma Inc. gained ¥21 in the last trading session, representing a 0.88% increase.
What is Astellas Pharma Inc. (4503) current market capitalization?
Astellas Pharma Inc. market cap is approximately 4.21 trillion.
What is Astellas Pharma Inc. (4503) Earnings Per Share (EPS)?
The trailing EPS is ¥162, and the forward EPS is ¥192.
What is Astellas Pharma Inc. (4503) Price-to-Earnings (P/E) ratio?
Astellas Pharma Inc. current P/E ratio is 14.47, with a forward P/E of 12.21.
What is Astellas Pharma Inc. (4503) EBITDA?
Astellas Pharma Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 101.42 billion.
Does Astellas Pharma Inc. (4503) pay dividends?
Yes. Astellas Pharma Inc. pays semiannual dividends with an annualized yield of 3.32% and an estimated annual payout of ¥78 per share.
When is the next ex-dividend date for Astellas Pharma Inc. (4503)?
The next ex-dividend date is scheduled for September 30, 2026.
How did Astellas Pharma Inc. (4503) perform in its most recent earnings report?
In the last report (June 30, 2026), Astellas Pharma Inc. posted an EPS surprise of 13.29% and a revenue surprise of -74.77%.
What is Astellas Pharma Inc. (4503) beta (volatility) score?
Astellas Pharma Inc. has a beta of 0.081, indicating lower volatility than the overall market.
